Skip to main content

Table 2 Prognostic factors for RFS by Cox proportional hazards regression model

From: Combination of the gamma-glutamyltransferase-to-prealbumin ratio and other indicators may be a novel marker for predicting the prognosis of patients with hepatocellular carcinoma undergoing locoregional ablative therapies

Factors

Univariate

Multivariate

HR (95% CI)

P

HR (95% CI)

P

Gender

1.72 (1.10–2.69)

0.016

1.63 (0.97–2.72)

0.061

Age

0.88 (0.62–1.23)

0.466

  

Diabetes mellitus

1.37 (0.93–2.01)

0.108

  

High blood pressure

1.03 (0.71–1.49)

0.866

  

History of smoking

1.51 (1.08–2.09)

0.014

1.11 (0.76–1.63)

0.579

History of drinking

1.22 (0.86–1.72)

0.248

  

Cirrhosis

1.28 (0.85–1.92)

0.222

  

Child-Pugh class

1.27 (0.90–1.78)

0.166

  

Antiviral therapy

0.77 (0.55–1.08)

0.135

  

Tumor number

2.36 (1.68–3.32)

< 0.0001

1.98 (1.38–2.85)

< 0.0001

Tumor size

1.60 (1.15–2.24)

0.005

0.93 (0.61–1.41)

0.748

Ablation method

0.90 (0.74–1.10)

0.341

  

Etiology

1.71 (0.89–1.53)

0.250

  

AFP

1.44 (1.13–1.82)

0.002

1.29 (1.01–1.66)

0.041

Viral load

1.00 (0.75–1.31)

0.291

  

ALT(U/L)

1.00 (0.99–1.01)

0.237

  

AST(U/L)

1.01 (0.99–1.02)

0.062

  

Total serum bilirubin (mg/dL)

1.00 (0.99–1.02)

0.369

  

Neutrophil count (10^9/L)

1.08 (0.98–1.19)

0.113

  

Lymphocyte count (10^9/L)

0.99 (0.75–1.31)

0.970

  

Platelet count (10^9/L)

1.00 (0.99–1.00)

0.147

  

Albumin

0.95 (0.91–0.98)

0.012

0.97 (0.92–1.01)

0.193

Globulin

1.03 (1.00–1.06)

0.015

1.01 (0.99–1.05)

0.206

Fibrinogen (mg/dL)

1.32 (1.12–1.55)

0.001

1.23 (1.00–1.50)

0.042

GPR

1.27 (1.13–1.41)

< 0.0001

1.15 (1.00–1.33)

0.048

  1. Abbreviations: AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, GPR gamma-glutamyltransferase to prealbumin ratio, the GPR was estimated as the gamma-glutamyltransferase divided by the prealbumin